A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
A legfontosabb adatok
- Ki végzi
- Anteris Technologies Ltd.
- Hol
- Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 1650 fő, tervezett
- Kezdés
- 2025. okt. 21.
- Várható befejezés
- 2038. márc.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- TAVR with DurAVR® THV
- TAVR with SAPIEN THV series or the Evolut THV series
- A regiszteradat frissítve
- 2026. július 15.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with severe aortic stenosis (a narrowed heart valve) who need a valve placed through a catheter (TAVR). A separate group is for people whose earlier surgical tissue valve has failed and who need a new valve placed inside it.
- Életkor
- 18 Years and older
- Nem
- All
- A betegség stádiuma
- Severe calcified narrowing of the person's own aortic valve, where the Heart Team agrees TAVR is needed. Or severe wear of a surgically placed tissue aortic valve, with high risk from surgery.
- Korábbi kezelés
- Main groups: no artificial heart valve already in place, in any position. Valve-in-valve group: must have an earlier surgically placed tissue aortic valve that is failing.
A részvétel fő kizáró okai
- Heart attack within the 30 days before treatment
- Severe leak of the mitral or tricuspid valve, or at least moderate narrowing of the mitral valve
- Untreated serious blockage of heart arteries that needs a procedure to reopen them
- Active bacterial infection of the heart lining in the last 3 months
- Expected to live less than 12 months after TAVR
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Native Aortic Stenosis Cohorts:
- The subject is a candidate for TAVR using the DurAVR® THV System, and a SAPIEN series THV system or an Evolut series THV System
- The local Heart Team agrees that the subject has an appropriate indication for, and will benefit from, TAVR due to native calcific valve severe aortic stenosis
- Subject understands the study requirements and the treatment procedure and provides written informed consent; ViV Registry Cohort:
- Severe degeneration of a surgically implanted aortic bioprosthetic valve
- Subject requires aortic valve replacement and is high surgical risk and is indicated for TAVR Valve-in-Valve procedure as determined by the Heart Team
- Subject understands the study requirements and the treatment procedure and provides written informed consent
Ki nem vehet részt
- Evidence of an acute myocardial infarction 30 days before randomization
- Failing surgical aortic bioprosthesis is unstable, rocking, or not structurally intact
- Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment
- Need for emergency surgery for any reason
- Untreated clinically significant coronary artery disease (CAD) requiring revascularization
- Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation
- Pre-existing prosthetic heart valve in the mitral, tricuspid or pulmonary position
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- Untreated clinically significant coronary artery disease (CAD) requiring revascularization
- GI bleeding within the past 3 months
- Native Aortic Stenosis Cohorts:
- Native aortic annulus size unsuitable for study THVs (investigational or control) based on CT imaging analysis
- Access vessel characteristics that would preclude safe placement of the introducer sheath (investigational or control)
- AV is unicuspid, Type 0 bicuspid, or is non-calcified
- Severe total aortic regurgitation
- Severe mitral or tricuspid regurgitation or ≥ moderate mitral stenosis
- Pre-existing mechanical or bioprosthetic valve in any position
- Active bacterial endocarditis in the last 3 months
- Estimated life expectancy (after TAVR) <12 months
- Subject is not a candidate for both arms (investigational and control) of the study
- Subject belongs to a vulnerable population; ViV Registry Cohort:
- Anatomy precluding safe placement of DurAVR THV
- Severe mitral or tricuspid regurgitation or ≥ moderate mitral stenosis
- Active bacterial endocarditis in the last 3 months
- Estimated life expectancy (after TAVR) <12 months
- Subject belongs to a vulnerable population
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Prospective, randomized, controlled, multicenter, international study.
A teljes eredeti leírásKevesebb
Up to 1054 subjects with a severe native calcific aortic stenosis who are determined by the local Heart Team to have an indication for Transcatheter Aortic Valve Replacement (TAVR), will be enrolled in the 'All Comers Randomized Cohort'. Subjects will be randomized 1:1 to receive either the DurAVR® THV System or any commercially available and approved Transcatheter Heart Valve (THV) from the SAPIEN series or the Evolut series and followed for 10 years.
After completion of the All Comers Randomized Cohort, up to 446 additional low-risk subjects will be randomized 1:1 in the 'Low Risk Randomized Continued Access Cohort'.
Up to 150 subjects with a failed surgical bioprosthesis who are deemed high surgical risk and who need valve-in-valve (ViV) TAVR will be enrolled in a separate nested registry (ViV Registry Cohort) and followed for 5 years. Subjects in the ViV Registry Cohort will only receive the DurAVR® THV.
A vizsgálat 2 csoportja
- DurAVR THVA vizsgált kezelés
DurAVR® THV implantation
Kezelés: TAVR with DurAVR® THV
- ControlMár használt kezelés, összehasonlításként
SAPIEN THV series or the Evolut THV series implantation
Kezelés: TAVR with SAPIEN THV series or the Evolut THV series
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective Randomized Trial Assessing the Safety and Effectiveness of the DurAVR® Biomimetic Valve Designed for Physiologic Flow Compared to Commercial TAVR Devices
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 15.